|
FUB-APINACA
FUB-APINACA (also known as AFUBINACA and FUB-AKB48) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is an analog of APINACA and 5F-APINACA where the pentyl chain has been replaced with fluorobenzyl. Pharmacology FUB-APINACA acts as a full agonist with a binding affinity of 1.06 nM at CB1 and 0.174 nM at CB2 cannabinoid receptors. Legal status In the United States, FUB-APINACA was temporarily emergency scheduled by the DEA in 2019. and made a permanent Schedule I Controlled Substance nationwide on April 7, 2022. Previously, it was illegal only in Alabama (listed as FUB-AKB48). Sweden's public health agency suggested classifying FUB-APINACA as a hazardous substance on November 10, 2014. See also * 5F-ADB * 5F-AMB * AB-FUBINACA * AB-CHFUPYCA * AB-PINACA * ADAMANTYL-THPINACA * ADB-CHMINACA * ADB-FUBINACA * ADB-PINACA * ADBICA * APP-FUBINACA * FAB-144 * MDMB-CH ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5F-APINACA
5F-APINACA (also known as 5F-AKB-48 or 5F-AKB48) is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with a 5-fluoropentyl chain on the indazole 1-position, and 5F-APINACA falls within the claims of this patent, as despite not being disclosed as an example, it is very similar to the corresponding pentanenitrile and 4-chlorobutyl compounds which are claimed as examples 3 and 4. 5F-APINACA was first identified in South Korea. It is expected to be a potent agonist of the CB1 receptor and CB2 receptor. Its metabolism has been described in literature. Pharmacology 5F-APINACA acts as a full agonist with a binding affinity of 1.94 nM at CB1 and 0.266 nM at CB2 cannabinoid receptors. Legality In the United States, 5F-APINACA is a Schedule I controlled substance. 5F-APINACA is an Anlage II controlled drug in Germany since July 2013. As of October 2 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
APINACA
APINACA (AKB48, ''N''-(1-adamantyl)-1-pentyl-1''H''-indazole-3-carboxamide) is a drug that acts as a reasonably potent agonist for the cannabinoid receptors, with a Ki of 304.5nM and an EC50 of 585nM at CB1. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis smoking blends, along with a related compound APICA. Structurally, it closely resembles cannabinoid compounds from a University of Connecticut patent (WO 2003/035005), but with a simple pentyl chain on the indazole 1-position, and APINACA falls within the claims of this patent despite not being disclosed as an example. Legality APINACA was made illegal in Japan in 2012, and was banned as a temporary class drug in New Zealand from 13 July 2012. APINACA has been banned in Latvia since 14 November 2013. Since 2013, APINACA has been a Schedule I controlled substance in the United States. It is al ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Schedule I Controlled Substance
This is the list of Schedule I drugs as defined by the United States Controlled Substances Act. 21 CFRbr>1308.11(CSA Sched I) with changes through (Oct 18, 2012). Retrieved September 6, 2013. The following findings are required for drugs to be placed in this schedule: # The drug or other substance has a high potential for abuse. # The drug or other substance has no currently accepted medical use in treatment in the United States. # There is a lack of accepted safety for use of the drug or other substance under medical supervision. Except as specifically authorized, it is illegal for any person: # to manufacture, distribute, or dispense, or possess with intent to manufacture, distribute, or dispense, a controlled substance; or # to create, distribute, dispense, or possess with intent to distribute or dispense, a counterfeit substance. Additional substances are added to the list by the Secretary of Health and Human Services pursuant to 21 CFR 1308.49. [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Indazole
Indazole, also called isoindazole, is a heterocyclic aromatic organic compound. This bicyclic compound consists of the fusion of benzene and pyrazole. Indazole is an amphoteric molecule which can be protonated to an indazolium cation or deprotonated to an indazolate anion. The corresponding ''pKa'' values are 1.04 for the equilibrium between indazolium cation and indazole and 13.86 for the equilibrium between indazole and indazolate anion. Indazole derivatives display a broad variety of biological activities. Indazoles are rare in nature. The alkaloids nigellicine, nigeglanine, and nigellidine are indazoles. Nigellicine was isolated from the widely distributed plant ''Nigella sativa'' L. (black cumin). Nigeglanine was isolated from extracts of ''Nigella glandulifera''. The Davis–Beirut reaction can generate 2''H''-indazoles. Indazole, C7H6N2, was obtained by E. Fischer (''Ann.'' 1883, 221, p. 280) by heating ortho-hydrazine cinnamic acid, : Some derivatives ; indazole-3- ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADBICA
ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. ADBICA is a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 0.69 nM and 1.8 nM respectively. Legal Status As of October 2015 ADBICA is a controlled substance in China. See also * 5F-AB-PINACA * 5F-ADB * 5F-ADBICA * 5F-AMB * 5F-APINACA * AB-FUBINACA * AB-CHFUPYCA * AB-CHMINACA * AB-PINACA * ADB-CHMINACA * ADB-FUBINACA * ADB-PINACA * ADB-P7AICA * APICA * APINACA * ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-CHMINACA
ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015. Side effects There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid. Legal status In the United States, ADB-CHMINACA is a Schedule I controlled substance. Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014. Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014. ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015. ADB-CHMINACA is illegal in Switzerland as of December 2015. M ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-FUBINACA
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. The (''S'')-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent and has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a ''tert''-butyl group. An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported. Side effects One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication. At least an additional 8 deaths in Hungary ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-PINACA
ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively. Like MDMB-FUBINACA, this compound contains an amino acid residue of tert-leucine. Side effects ADB-PINACA has been linked to multiple hospitalizations and deaths due to its use. Metabolism Nineteen ADB-PINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic reactions included pentyl hydroxylation, hydroxylation followed by oxidation (ketone formation), and glucuronidation. Legality ADB-PINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015. In the United States, it is a Schedule I controlled substance. As of October 2015 ADB-PINACA is a controlled substance in China. See also * 5F-AB-PINACA * 5F-ADB * 5F-ADB-PINACA ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FAB-144
FAB-144 is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is the indazole analogue of XLR-11. Legal status Sweden's public health agency suggested classifying FAB-144 as a hazardous substance on November 10, 2014. See also * JWH-018 * STS-135 * UR-144 UR-144 (TMCP-018, KM-X1, MN-001, YX-17) is a drug invented by Abbott Laboratories, that acts as a selective full agonist of the peripheral cannabinoid receptor CB2, but with much lower affinity for the psychoactive CB1 receptor. Pharmacology ... References Cannabinoids Designer drugs Organofluorides Indazoles Cyclopropanes {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
APP-FUBINACA
APP-FUBINACA is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. Pharmacological testing showed APP-FUBINACA to have only moderate affinity for the CB1 receptor, with a Ki of 708 nM, while its EC50 was not tested. It contains a phenylalanine amino acid residue in its structure. Legality Sweden's public health agency suggested to classify APP-FUBINACA as hazardous substance on March 24, 2015. See also * 5F-AB-PINACA * 5F-ADB * 5F-AMB * 5F-APINACA * AB-FUBINACA * AB-CHFUPYCA * AB-CHMINACA * AB-PINACA * ADB-CHMINACA * ADB-FUBINACA * ADB-PINACA * ADBICA * APICA * APINACA * APP-BINACA * BMS-F * MDMB-CHMICA * MDMB-FUBINACA * PX-1 * PX-2 * PX-3 PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic m ... References Cannabinoids Designer drugs Ind ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
